Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2016. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| October 13, 2016 | Ordinary Shares (25 pence each) | £17.0319 | 5,394.378 shares |
Note: Total volume is the aggregate of 12 individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the acquisition of shares by executives and their associates.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of all reported transactions was the acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on October 13, 2016. All transactions were executed on the London Stock Exchange (XLON).
Key Facts for Investor Verification
- Transaction Type: All reported trades were acquisitions via dividend re-investment plans, not open market purchases or sales.
- Participants: Transactions involved 11 PDMRs/PCAs, including CEO Sir Andrew Witty, CFO Mr S Dingemans, and CEO Designate Ms E Walmsley.
- Share Price: The uniform execution price for all transactions was £17.0319 per share.
- Scope: This filing does not contain financial performance data; investors should refer to Form 20-F or quarterly reports for revenue and earnings.